Divi's Laboratories Ltd
DIVISLABDivi's Laboratories Ltd
DIVISLAB
Price Chart
Scorecard
Performance
AvgPrice return has been average, nothing exciting
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
HighShowing good signs of profitability & efficiency
Entry point
AvgThe stock is overpriced but is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| 76.38 | 11.63 | 0.50% |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 48.65 | 6.19 | 0.55% |
Forecast & Ratings
Detailed Forecast from 22 analysts
Price
Price Upside
Earnings
Earnings Growth
Revenue
Rev. Growth
Company Profile
Divi's Laboratories Limited is engaged in manufacturing and sale of active pharmaceutical ingredients (APIs) and Intermediates. Its products include Generic APIs, Intermediates, Peptide Building Blocks and Carotenoids.
Peers
Compare with peersÂGet more out of Tickertape, Go Pro!
Customise key metrics, see detailed forecasts, download stock data and more
Forecasts
Price
Revenue
Earnings
Price Forecast
All values in ₹
All values in ₹
Revenue Forecast
All values in ₹ Thousand cr.
All values in ₹ Thousand cr.
Earnings Per Share Forecast
All values in ₹
All values in ₹
Income
Balance Sheet
Cash Flow
Income Statement
| Financial Year | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | TTM | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 3,873.80 | 4,139.23 | 4,004.93 | 5,101.89 | 5,584.05 | 7,031.96 | 9,073.70 | 8,112.00 | 8,184.00 | 9,424.00 | ||||||||||
Raw Materials | 1,478.71 | 1,608.36 | 1,567.94 | 2,169.72 | 2,256.99 | 2,455.40 | 3,552.07 | 3,087.00 | 3,300.00 | 6,266.00 | ||||||||||
| Power & Fuel Cost | 180.34 | 198.80 | 228.73 | 248.78 | 280.73 | 319.15 | 392.33 | 496.00 | 477.00 | |||||||||||
| Employee Cost | 361.19 | 499.90 | 456.06 | 542.27 | 621.05 | 825.76 | 946.16 | 975.00 | 1,094.00 | |||||||||||
| Selling & Administrative Expenses | 134.18 | 154.26 | 200.48 | 175.70 | 228.23 | 287.84 | 345.20 | 393.00 | 358.00 | |||||||||||
| Operating & Other expenses | 203.61 | 155.88 | 175.53 | -63.23 | 184.21 | 220.08 | -159.07 | 447.00 | 410.00 | |||||||||||
EBITDA | 1,515.77 | 1,522.03 | 1,376.19 | 2,028.65 | 2,012.84 | 2,923.73 | 3,997.01 | 2,714.00 | 2,545.00 | 3,158.00 | ||||||||||
| Depreciation/Amortization | 118.18 | 123.33 | 142.49 | 168.90 | 186.24 | 255.59 | 311.51 | 343.00 | 378.00 | 390.00 | ||||||||||
| PBIT | 1,397.59 | 1,398.70 | 1,233.70 | 1,859.75 | 1,826.60 | 2,668.14 | 3,685.50 | 2,371.00 | 2,167.00 | 2,768.00 | ||||||||||
| Interest & Other Items | 4.74 | 3.36 | 2.37 | 4.68 | 7.14 | 2.10 | 2.00 | 2.00 | 4.00 | 3.00 | ||||||||||
| PBT | 1,392.85 | 1,395.34 | 1,231.33 | 1,855.07 | 1,819.46 | 2,666.04 | 3,683.50 | 2,369.00 | 2,163.00 | 2,765.00 | ||||||||||
| Taxes & Other Items | 267.06 | 334.92 | 354.32 | 502.33 | 442.92 | 681.75 | 723.05 | 545.00 | 563.00 | 698.00 | ||||||||||
| Net Income | 1,125.79 | 1,060.42 | 877.01 | 1,352.74 | 1,376.54 | 1,984.29 | 2,960.45 | 1,824.00 | 1,600.00 | 2,067.00 | ||||||||||
| EPS | 42.41 | 39.95 | 33.04 | 50.96 | 51.85 | 74.75 | 111.52 | 68.71 | 60.27 | 77.86 | ||||||||||
| DPS | 10.00 | 10.00 | 10.00 | 16.00 | 16.00 | 20.00 | 30.00 | 30.00 | 30.00 | 30.00 | ||||||||||
| Payout ratio | 0.24 | 0.25 | 0.30 | 0.31 | 0.31 | 0.27 | 0.27 | 0.44 | 0.50 | 0.39 |
Company Updates
Annual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFPeers & Comparison
Health CareLabs & Life Sciences Services
Valuation
Technical
Forecast
Compare valuation on Screener| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| Divi's Laboratories Ltd | 98.67 | 11.63 | 0.50% |
| Syngene International Ltd | 56.83 | 6.81 | 0.17% |
| Aarti Pharmalabs Ltd | 29.99 | 3.70 | 0.42% |
| Dishman Carbogen Amcis Ltd | -23.61 | 0.64 | — |
Price Comparison
Compare DIVISLAB with any stock or ETFShareholdings
Promoter Holdings Trend
Total Promoter Holding
In last 6 months, promoter holding in the company has almost stayed constant
Low Pledged Promoter Holding
Pledged promoter holdings is insignificant
Institutional Holdings Trend
Total Retail Holding
In last 3 months, retail holding in the company has almost stayed constant
Foreign Institutional Holding
In last 3 months, foreign institutional holding of the company has almost stayed constant
Shareholding Pattern
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Shareholding History
Mutual Funds Holding Trend
Mutual Fund Holding
In last 3 months, mutual fund holding of the company has almost stayed constant
Top 5 Mutual Funds holding Divi's Laboratories Ltd
| Funds (Top 5) | The rupee value of the stock held by the fund divided by the stock’s market cap Market-cap held | Percentage of the fund’s portfolio invested in the stock Weight | Change in the portfolio weight of the stock over the last 3 months 3M holding change | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months Portfolio rank(3M change) |
|---|---|---|---|---|
The rupee value of the stock held by the fund divided by the stock’s market cap 1.6664% | Percentage of the fund’s portfolio invested in the stock 3.70% | Change in the portfolio weight of the stock over the last 3 months -0.56% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 6/103 (-2) | |
The rupee value of the stock held by the fund divided by the stock’s market cap 0.9652% | Percentage of the fund’s portfolio invested in the stock 3.10% | Change in the portfolio weight of the stock over the last 3 months -0.24% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 11/55 (-2) | |
The rupee value of the stock held by the fund divided by the stock’s market cap 0.9303% | Percentage of the fund’s portfolio invested in the stock 4.23% | Change in the portfolio weight of the stock over the last 3 months -0.56% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 10/33 (-4) |
Compare 3-month MF holding change on Screener
smallcases
Looks like this stock is not in any smallcase yet.
Events
Dividend Trend
No Dividend Cuts
DIVISLAB has increased or maintained dividend levels over the last 5 years
Dividend Yield
Current dividend yield is 0.50%. An investment of ₹1,000 in the stock is expected to generate dividend of ₹5.04 every year
Dividends
Corp. Actions
Announcements
Legal Orders
Upcoming Dividends
No upcoming dividends are available
Past Dividends
Cash Dividend
Ex DateEx DateAug 2, 2024
Dividend/Share
₹30.00
Ex DateEx Date
Aug 2, 2024
Cash Dividend
Ex DateEx DateAug 11, 2023
Dividend/Share
₹30.00
Ex DateEx Date
Aug 11, 2023
Cash Dividend
Ex DateEx DateAug 11, 2022
Dividend/Share
₹30.00
Ex DateEx Date
Aug 11, 2022
Cash Dividend
Ex DateEx DateAug 17, 2021
Dividend/Share
₹20.00
Ex DateEx Date
Aug 17, 2021
Cash Dividend
Ex DateEx DateFeb 25, 2020
Dividend/Share
₹16.00
Ex DateEx Date
Feb 25, 2020
Divis Laboratories Ltd rose for a fifth straight session today. The stock is quoting at Rs 6146.65, up 0.38% on the day as on 12:44 IST on the NSE. The benchmark NIFTY is down around 0.38% on the day, quoting at 23607. The Sensex is at 77975.37, down 0.38%. Divis Laboratories Ltd has gained around 4.04% in last one month. Meanwhile, Nifty Pharma index of which Divis Laboratories Ltd is a constituent, has gained around 5.07% in last one month and is currently quoting at 21868.5, up 0.83% on the day. The volume in the stock stood at 2.2 lakh shares today, compared to the daily average of 4.45 lakh shares in last one month. The benchmark February futures contract for the stock is quoting at Rs 6170.35, up 0.37% on the day. Divis Laboratories Ltd is up 64.71% in last one year as compared to a 7.64% jump in NIFTY and a 18.78% jump in the Nifty Pharma index.The PE of the stock is 78.43 based on TTM earnings ending December 24.Powered by Capital Market - Live
Divis Laboratories Ltd is up for a third straight session today. The stock is quoting at Rs 6074, up 3.23% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is up around 1.05% on the day, quoting at 23606.2. The Sensex is at 78049.17, up 1.12%. Divis Laboratories Ltd has gained around 3.1% in last one month. Meanwhile, Nifty Pharma index of which Divis Laboratories Ltd is a constituent, has gained around 6.05% in last one month and is currently quoting at 21361.6, up 1.48% on the day. The volume in the stock stood at 10.02 lakh shares today, compared to the daily average of 4.03 lakh shares in last one month. The benchmark February futures contract for the stock is quoting at Rs 6101.05, up 2.96% on the day. Divis Laboratories Ltd is up 64.18% in last one year as compared to a 8.43% jump in NIFTY and a 18.5% jump in the Nifty Pharma index.The PE of the stock is 85.11 based on TTM earnings ending September 24.Powered by Capital Market - Live
Net profit of Divi's Laboratories rose 64.53% to Rs 589.00 crore in the quarter ended December 2024 as against Rs 358.00 crore during the previous quarter ended December 2023. Sales rose 25.01% to Rs 2319.00 crore in the quarter ended December 2024 as against Rs 1855.00 crore during the previous quarter ended December 2023. ParticularsQuarter EndedDec. 2024Dec. 2023% Var. Sales2319.001855.00 25 OPM %32.0426.36 - PBDT825.00584.00 41 PBT726.00489.00 48 NP589.00358.00 65 Powered by Capital Market - Live
Total income grew by 23.13% year on year (YoY) to Rs 2,401 crore in the quarter ended 31 December 2024. Profit before tax for the quarter was at Rs 726 crore, up 48.47% from Rs 489 crore reported in the same period a year ago. Total expenses stood at Rs 1,675 crore in the third quarter of FY25, up 14.65% on YoY basis. Cost of material consumed was at Rs 1,021 crore (up 28.59% YoY) and employee benefit expenses stood at Rs 297 crore (up 10.82% YoY) during the period under review. Forex gain for the current quarter amounted to Rs 10 crore as against a gain of Rs 18 crore posted in Q3 FY24. On nine-month basis, the company's net profit climbed 43.97% to Rs 1,529 crore on 22.25% rise in revenue from operations to Rs 6,775 crore in 9M FY25 over 9M FY24. Forex gain for the nine-month period amounted to Rs 38 crore as against a gain of Rs 32 crore posted in same period a year ago. Divi's Laboratories is engaged in the manufacture of active pharmaceutical ingredients, intermediates and nutraceutical ingredients. Powered by Capital Market - Live
Divis Laboratories will hold a meeting of the Board of Directors of the Company on 3 February 2025.Powered by Capital Market - Live
Divis Laboratories has commenced commercial operations from a part of the Phase I of Unit III greenfield project at Ontimamidi Village (Kona), Thondangi Mandal, Kakinada, Andhra Pradesh from 01 January 2025. The phase I of the Unit III greenfield project of the Company at Kakinada, Andhra Pradesh is being implemented on 200 acres of 500 acres Unit III site, with an estimated investment between Rs 1,200 crore to Rs 1,500 crore. Powered by Capital Market - Live
Divis Laboratories Ltd rose for a fifth straight session today. The stock is quoting at Rs 6075.75, up 1.29% on the day as on 12:44 IST on the NSE. The benchmark NIFTY is up around 1.58% on the day, quoting at 24284.95. The Sensex is at 80244.25, up 1.42%. Divis Laboratories Ltd has added around 4.49% in last one month. Meanwhile, Nifty Pharma index of which Divis Laboratories Ltd is a constituent, has added around 2.89% in last one month and is currently quoting at 21962.05, up 1.07% on the day. The volume in the stock stood at 1.57 lakh shares today, compared to the daily average of 4.48 lakh shares in last one month. The benchmark November futures contract for the stock is quoting at Rs 6100.3, up 1.47% on the day. Divis Laboratories Ltd is up 61.58% in last one year as compared to a 22.1% gain in NIFTY and a 39.6% gain in the Nifty Pharma index.The PE of the stock is 86.7 based on TTM earnings ending September 24.Powered by Capital Market - Live
Total income grew by 22.51% year on year (YoY) to Rs 2,444 crore in the quarter ended 30 September 2024. Profit before tax for the quarter was at Rs 722 crore, up 53.94% from Rs 469 crore reported in the same period a year ago. Total expenses stood at Rs 1,722 crore in second quarter of FY25, up 12.84% on YoY basis. Cost of material consumed was at Rs 976 crore (up 37.27% YoY) and employee benefit expenses stood at Rs 304 crore (up 14.29% YoY) during the period under review. Forex gain for the current quarter amounted to Rs 29 crore as against a gain of Rs 11 crore posted in Q2 FY24. On half yearly basis, the company's net profit climbed 33.52% to Rs 940 crore on 20.86% rise in revenue from operations to Rs 4,456 crore in H1 FY25 over H1 FY24. Forex gain for the six month period amounted to Rs 28 crore as against a gain of Rs 14 crore posted in same period a year ago. Divi's Laboratories is engaged in the manufacture of active pharmaceutical ingredients, intermediates and nutraceutical ingredients. Shares of Divi's Laboratories declined 0.34% to end at Rs 5,938.15 on Friday, 8 November 2024. Powered by Capital Market - Live
Net profit of Divi's Laboratories rose 46.55% to Rs 510.00 crore in the quarter ended September 2024 as against Rs 348.00 crore during the previous quarter ended September 2023. Sales rose 22.47% to Rs 2338.00 crore in the quarter ended September 2024 as against Rs 1909.00 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales2338.001909.00 22 OPM %30.6225.09 - PBDT821.00564.00 46 PBT722.00469.00 54 NP510.00348.00 47 Powered by Capital Market - Live
Divis Laboratories will hold a meeting of the Board of Directors of the Company on 9 November 2024Powered by Capital Market - Live
Higher than Industry Revenue Growth
Over the last 5 years, revenue has grown at a yearly rate of 9.91%, vs industry avg of 4.53%
Increasing Market Share
Over the last 5 years, market share increased from 41.55% to 46.37%
Lower than Industry Net Income
Over the last 5 years, net income has grown at a yearly rate of 3.41%, vs industry avg of 5.93%